DG
GLMD icon

Delek Group’s Galmed Pharmaceuticals GLMD Stock Holding History

Delek Group’s Portfolio GLMD Stock Details GLMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q2 		$176K Buy
17
+2
+13% +$20.6K 0.01% 209
2019
Q1 		$173K Buy
+15
New +$174K 0.01% 202

Other funds holding GLMD

BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
6CM
683 Capital Management New York $2.04B AUM 94.26% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return
II
Ibex Investors Denver, Colorado $194M AUM 23.58% 1-Year Est. Return
MIH
Meitav Investment House Bene-Beraq, Israel $14.9B AUM 46.8% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
KCM
Knoll Capital Management Miami, Florida $179M AUM 63.61% 1-Year Est. Return
FMBTD
First Midwest Bank Trust Division Joliet, Illinois $777M AUM 29.48% 1-Year Est. Return
RJA
Raymond James & Associates St Petersburg, Florida $164B AUM 33.91% 1-Year Est. Return

Delek Group's GLMD Position: Q2 2019 in Review

Delek Group increased its Galmed Pharmaceuticals (GLMD) stake by 13% in Q2 2019, buying an estimated $20.6K and bringing the position to 17 shares worth $176K. The position accounts for 0.01% of the portfolio, ranked #209.

Delek Group first reported a position in GLMD in Q1 2019 and has held it in 2 quarters since. 31 funds tracked by Wall St. Rank hold GLMD as of Q2 2019.

  • Delek Group held 17 shares of Galmed Pharmaceuticals worth $176K as of Q2 2019.
  • Delek Group bought 2 Galmed Pharmaceuticals shares in Q2 2019, an estimated $20.6K.
  • Galmed Pharmaceuticals made up 0.01% of Delek Group's portfolio in Q2 2019, its #209 holding.
  • Delek Group first reported a position in Galmed Pharmaceuticals in Q1 2019 and has held it in 2 quarters since.
  • 31 funds tracked by Wall St. Rank held Galmed Pharmaceuticals as of Q2 2019.

Based on Delek Group's 13F filing for Q2 2019, filed 8 Aug 2019.